Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Imunon ( (IMNN) ) has shared an announcement.
On May 23, 2025, Imunon, Inc. announced a securities purchase agreement with institutional and accredited investors for a private placement of common stock and warrants, expected to close around May 27, 2025. The company anticipates gross proceeds of $3.25 million, with a potential additional $6.5 million if all warrants are exercised. The proceeds will be used for working capital and general corporate purposes. The company has agreed to file a registration statement with the SEC and plans to hold a stockholder meeting to obtain necessary approvals for the warrants. H.C. Wainwright & Co. is the lead placement agent for this transaction.
The most recent analyst rating on (IMNN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.
Spark’s Take on IMNN Stock
According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.
Imunon’s financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock’s risky profile, with a negative P/E ratio and no dividend yield.
To see Spark’s full report on IMNN stock, click here.
More about Imunon
IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments that utilize the body’s natural mechanisms to generate effective responses across various human diseases. The company is advancing its non-viral DNA technology, with its lead clinical program, IMNN-001, targeting advanced ovarian cancer, and has completed multiple clinical trials.
Average Trading Volume: 7,448,895
Technical Sentiment Signal: Hold
Current Market Cap: $20.35M
See more data about IMNN stock on TipRanks’ Stock Analysis page.